國家衛生研究院 NHRI:Item 3990099045/2966

NHRI > National Institute of Cancer Research > Jacqueline Whang-Peng(1996-2007) > Periodical Articles > Item 3990099045/2966

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2966

Title:	alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma
Other Titles:	α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma
Authors:	Chen, LT;Liu, TW;Chao, Y;Shiah, HS;Chang, JY;Juang, SH;Chen, SC;Chuang, TR;Chin, YH;Whang-Peng, J
Contributors:	National Institute of Cancer Research
Abstract:	Background: Radiographic measurements do not always reflect the biological response of hepatocellular carcinoma to drug therapy. Aims: To evaluate the clinical implications of tumour marker (alpha-fetoprotein) response in advanced hepatocellular carcinoma patients with thalidomide treatment. Patients and methods: Forty-two advanced hepatocellular carcinoma patients with baseline alpha-fetoprotein levels above 200 ng/mL and thalidomide therapy were included. Serum alpha-fetoprotein levels were measured every 4 weeks. alpha-fetoprotein response was defined as a 50% or greater reduction of alpha-fetoprotein levels for 4 or more weeks during treatment. Radiographic response was assessed by World Health Organization criteria; survivals were estimated by Kaplan-Meier method and prognostic factors were assessed by Cox's proportional hazard model. Results: With intention-to-treat analysis, radiographic response and alpha-fetoprotein response were obtained in 7% (three of 42, 95% confidence interval: 0-15) and 24% (10 of 42, 95% CI: 10-38) of patients, respectively. All radiographic response was observed in alpha-fetoprotein responders. Multivariate analyses showed alpha-fetoprotein response was independent prognostic factor for both progression-free survival (relative risk = 0.394, 95% CI: 0.189-0.820, P = 0.013) and overall survival (relative risk = 0.241, 95% CI: 0.096-0.606, P =0.003), whereas radiographic response was not. Conclusion: alpha-fetoprotein response can more accurately reflect the biological response of advanced hepatocellular carcinoma to thalidomide therapy than radiographic response.
Keywords:	Gastroenterology & Hepatology;Pharmacology & Pharmacy
Date:	2005-08-01
Relation:	Alimentary Pharmacology and Therapeutics. 2005 Aug;22(3):217-226.
Link to:	http://dx.doi.org/10.1111/j.1365-2036.2005.02547.x
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0269-2813&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000230886800007
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=23844534451
Appears in Collections:	[Jacqueline Whang-Peng(1996-2007)] Periodical Articles [Tsang-Wu Liu] Periodical Articles [Her-Shyong Shiah(1996-2012)] Periodical Articles [Jang-Yang Chang] Periodical Articles [Shin-Hun P. Juang(1997-2004)] Periodical Articles [Li-Tzong Chen] Periodical Articles

Files in This Item:

File	Description	Size	Format
000230886800007.pdf		147Kb	Adobe PDF	1039	View/Open

Loading...